WASHINGTON (AP) — The Food and Drug Administration on Thursday announced the first round of experimental drugs that will receive drastically expedited reviews at the agency, part of an effort to prioritize medicines the Trump administration deems as "supporting U.S. national interests."

Dr.

📰

Continue Reading on Manila Bulletin

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →